Track market-moving stories before they get noisy

Wall Street analysts expect Spotify (SPOT - Free Report) to post quarterly earnings of $3.12 per share in its upcoming report, which indicates a year-over-year decline of 18.5%. Revenues are expected to be $5.73 billion, up 14.8% from the year-ago quarter.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

That said, let's delve into the average estimates of some Spotify metrics that Wall Street analysts commonly model and monitor.

The collective assessment of analysts points to an estimated 'Total Monthly Active Users (MAUs)' of 790.07 million. Compared to the current estimate, the company reported 713.00 million in the same quarter of the previous year.

Analysts predict that the 'Premium Subscribers' will reach 305.06 million. Compared to the current estimate, the company reported 281.00 million in the same quarter of the previous year.

Analysts forecast 'Ad-Supported MAUs' to reach 499.83 million. Compared to the current estimate, the company reported 446.00 million in the same quarter of the previous year.

View all Key Company Metrics for Spotify here>>>

Spotify shares have witnessed a change of +4.1% in the past month, in contrast to the Zacks S&P 500 composite's +1.5% move. With a Zacks Rank #4 (Sell), SPOT is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Robertson Stephens Wealth Management LLC boosted its stake in Strategy Inc (NASDAQ:MSTR – Free Report) by 83.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,924 shares of the software maker’s stock after purchasing an additional 4,048 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Strategy were worth $1,366,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MSTR. Frank Rimerman Advisors LLC acquired a new position in shares of Strategy in the 3rd quarter worth approximately $235,000. Counterpoint Mutual Funds LLC bought a new position in Strategy during the third quarter worth $439,000. St. Louis Financial Planners Asset Management LLC bought a new position in Strategy during the third quarter worth $446,000. Parisi Gray Wealth Management bought a new position in Strategy during the third quarter worth $547,000. Finally, Cyndeo Wealth Partners LLC lifted its holdings in Strategy by 533.6% in the third quarter. Cyndeo Wealth Partners LLC now owns 17,887 shares of the software maker’s stock valued at $2,738,000 after buying an additional 15,064 shares during the period. 59.84% of the stock is owned by institutional investors.

Insider Activity
In related news, Director Jarrod Patten sold 2,775 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $125.33, for a total value of $347,790.75. Following the transaction, the director directly owned 28,406 shares in the company, valued at $3,560,123.98. This trade represents a 8.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 14,100 shares of company stock valued at $1,815,669. 5.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth
MSTR has been the topic of a number of research analyst reports. Alliance Global Partners assumed coverage on shares of Strategy in a research report on Tuesday, September 1st. They set a “buy” rating and a $217.00 price target on the stock. Benchmark reissued a “buy” rating and issued a $435.00 price objective (down from $570.00) on shares of Strategy in a research report on Monday, July 27th. UBS Group reissued a “buy” rating on shares of Strategy in a research note on Friday, July 31st. HC Wainwright set a $325.00 target price on Strategy in a research report on Monday, August 3rd. Finally, TD Cowen decreased their target price on Strategy from $400.00 to $260.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Strategy currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.13.
Read Our Latest Analysis on MSTR

More Strategy News
Here are the key news stories impacting Strategy this week:

Positive Sentiment: Cantor Fitzgerald raised its price target to $208 from $186 and maintained an “overweight” rating, implying substantial upside based on Strategy’s Bitcoin holdings and treasury strategy. Cantor Fitzgerald raises Strategy price target
Positive Sentiment: Strategy plans to maintain a 12% annualized dividend rate on its STRC preferred shares and begin daily cash dividends in November, subject to shareholder approval. The move is intended to support STRC’s trading near its $100 par value and improve investor confidence in the preferred securities. Strategy daily dividends
Neutral Sentiment: Strategy continues to hold a large Bitcoin position—reported at approximately 848,250 BTC—and CEO Michael Saylor remains bullish on broader institutional and banking adoption of Bitcoin. This supports the long-term investment case but leaves MSTR highly exposed to cryptocurrency volatility. Michael Saylor Bitcoin outlook
Negative Sentiment: MSCI adopted new eligibility rules for non-operating companies that could remove Strategy from major global indexes. The final deletion list is expected November 11, with implementation later in the month. Analysts estimate index-tracking funds could be forced to sell as much as $2.8 billion of MSTR, creating a significant source of selling pressure even if Bitcoin prices stabilize. MSCI index exclusion rules
Negative Sentiment: Recent momentum has weakened as Bitcoin’s rally and crypto ETF inflows lost steam. MSTR has also begun diverging from Bitcoin’s performance, raising concern that index-related risks and its premium to underlying Bitcoin holdings are becoming more important drivers of the stock. Strategy stock analysis

Strategy Stock Performance
Shares of MSTR opened at $136.83 on Monday. The stock has a 50-day moving average of $135.78 and a 200-day moving average of $131.33. The company has a market cap of $52.57 billion, a PE ratio of -1.41 and a beta of 3.56. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.39 and a quick ratio of 5.39. Strategy Inc has a one year low of $81.81 and a one year high of $306.16.

Strategy (NASDAQ:MSTR – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The software maker reported ($24.45) EPS for the quarter, missing analysts’ consensus estimates of ($2.19) by ($22.26). The firm had revenue of $122.37 million during the quarter, compared to analyst estimates of $122.90 million. Strategy had a negative net margin of 6,102.95% and a negative return on equity of 74.18%. The company’s revenue was up 6.9% on a year-over-year basis. During the same period last year, the business posted $32.52 EPS. On average, equities research analysts predict that Strategy Inc will post -23.74 EPS for the current fiscal year.

Strategy Company Profile
(Free Report)

Strategy, formerly known as MicroStrategy, Incorporated (NASDAQ: MSTR) is a global provider of enterprise analytics and mobility software. The company’s flagship platform offers business intelligence, data discovery, and advanced visualizations that enable organizations to analyze large volumes of data and deliver actionable insights. In addition to traditional on-premises deployments, Strategy provides a range of cloud-based services and managed offerings that allow customers to leverage the power of its analytics tools without managing complex infrastructure.

Founded in 1989 by Michael J.

See Also

Five stocks we like better than Strategy
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Want to see what other hedge funds are holding MSTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strategy Inc (NASDAQ:MSTR – Free Report).

Receive News & Ratings for Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strategy and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways HPs non-GAAP operating margin fell 60 basis points to 6.5% in fiscal Q3 2026.HPs non-GAAP operating margin fell 60 basis points to 6.5% in fiscal Q3 2026.Personal Systems margins may bottom in Q4 fiscal 2026 before improving into fiscal 2027.
HP Inc. (HPQ - Free Report) is experiencing margin pressure as rising memory and storage costs increase component expenses across its Personal Systems business. However, disciplined pricing, cost-reduction initiatives and a shift toward higher-value products could help the company protect profitability despite a challenging operating environment.

In the third quarter of fiscal 2026, HP reported revenues of $15.7 billion, up 12.5% year over year. However, its non-GAAP operating margin declined 60 basis points to 6.5%, while gross margin fell to 18.8% amid higher commodity costs and an increased contribution from Personal Systems. The segment generated $11.8 billion in revenues, up 18%, but its operating margin declined 80 basis points to 4.6%. Although pricing actions and cost reductions partially offset rising expenses, the pressure on profitability remains evident.

HP is pursuing a four-pillar mitigation strategy encompassing supply security, demand shaping, targeted cost reductions and disciplined pricing. The company has qualified new suppliers, adjusted product configurations and implemented repricing initiatives. Product redesign, platform optimization and revisions to long-term pricing contracts are expected to provide additional benefits as these measures take effect. HP also reported improved memory supply availability and higher order fulfillment rates, supporting its ability to meet customer demand.

Portfolio optimization represents another important margin lever. HP is prioritizing premium PCs, AI-enabled computers, workstations and higher-margin services and peripherals. These categories can improve revenue mix and help offset lower unit shipments. Management also expects edge AI workloads and related offerings to create opportunities for profitable growth. Nevertheless, near-term pressures persist. HP expects memory and storage costs to rise further, with Personal Systems margins likely reaching a low point in the fourth quarter of fiscal 2026 before improving into fiscal 2027.

How Competitors Fare Against HPQThe AI PC business in which HPQ claims to lead the market is facing considerable competition from Dell Technologies (DELL - Free Report) and Lenovo (LNVGY - Free Report) .

Dell has numerous workstations that offer AI capabilities. These workstations are DELL XPS 13, Inspiron 14 Plus, Inspiron 14, Latitude 7455 and Latitude 5455. Lenovo’s lineup of AI computers includes Lenovo ThinkPad X1 Carbon 10th Gen and later, Lenovo Yoga 9i and Lenovo ThinkBook Plus Gen 3.

HPQ’s Price Performance, Valuation and EstimatesHPQ shares have appreciated 34.7% year to date, outperforming the Zacks Computer - Micro Computers industry and the Zacks Computer and Technology sector’s return of 31.3% and 15.8%, respectively.

HPQ YTD Performance Chart
Image Source: Zacks Investment Research

Despite the appreciation in the share price, HPQ trades at a discount. From a valuation standpoint, HPQ trades at a forward price-to-sales ratio of 0.45, below the industry’s 8.5. The discounted valuation is further substantiated by the Zacks Value Score of A.

HPQ Forward 12-Month (P/S) Valuation Chart
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for HPQ’s fiscal 2026 revenues suggests year-over-year growth of 3.5%. Estimates have remained unchanged in the past 30 days.

Image Source: Zacks Investment Research

HPQ sports Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Key Takeaways SLB is set to report Q3 earnings on Oct. 23, following four consecutive earnings beats averaging 4.94%.Q3 earnings are projected to fall 10.1% to 62 cents per share, while revenues are expected to rise 4.04%.Higher oil prices may boost demand for SLB's services, but its Earnings ESP of -1.45% signals caution. SLB (SLB - Free Report) is set to report third-quarter 2026 results on Oct. 23, before the opening bell.

In the last reported quarter, its earnings of 55 cents per share beat the Zacks Consensus Estimate of 51 cents, driven by growth in Digital and Production Systems, along with broad-based gains outside the Middle East. The oilfield service player’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 4.94%. This is depicted in the graph below:

Estimate Trend for SLBThe Zacks Consensus Estimate for third-quarter earnings per share of 62 cents hasn’t seen any revisions over the past seven days. The estimated figure indicates a 10.1% decline from the prior-year reported number.

The Zacks Consensus Estimate for revenues of $9.3 billion implies a 4.04% increase from the year-ago recorded figure.

Factors to Consider Ahead of SLB Q3 EarningsTo have an idea of how oil prices behaved in the September quarter, let's analyze the commodity prices from the data provided by the U.S. Energy Information Administration (“EIA”). The average Cushing, OK, WTI spot prices for July, August and September of this year were $80.46, $83.90 and $97.31 per barrel, respectively, per EIA data. Commodity prices were $68.39, $64.86 and $63.96 per barrel, respectively, in prior-year, respective quarters, according to the EIA.

A constructive oil-price backdrop, driven by the Middle East conflicts, aided the exploration and production businesses in the September quarter of this year. This, in turn, is expected to have backed demand for SLB’s oilfield services.

Earnings WhispersOur proven model doesn’t indicate an earnings beat for SLB this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. That isn’t the case here, as you will see below.

Earnings ESP: SLB currently has an Earnings ESP of -1.45%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: SLB currently carries a Zacks Rank #3 at present.

Stocks to ConsiderHere are some stocks that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.

Baker Hughes Company (BKR - Free Report) has an Earnings ESP of +1.15% and currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Baker Hughes is scheduled to release third-quarter 2026 earnings on Oct. 27. The Zacks Consensus Estimate for BKR’s earnings is pegged at 65 cents per share, indicating a 4.4% decline from the prior-year reported figure.

EOG Resources (EOG - Free Report) has an Earnings ESP of +0.59% and flaunts a Zacks Rank #1 at present. EOG is scheduled to release third-quarter 2026 earnings on Nov. 5.

The Zacks Consensus Estimate for EOG’s earnings is pegged at $4.39 per share, suggesting a 62% improvement from the prior-year reported figure.

BP plc (BP - Free Report) has an Earnings ESP of +7.29% and a Zacks Rank #1. BP is scheduled to release third-quarter 2026 earnings on Oct. 30.

The Zacks Consensus Estimate for BP’s earnings is pegged at $2.09 per share, suggesting a 146% increase from the prior-year reported figure.

SteelPeak Wealth LLC bought a new stake in Atmos Energy Corporation (NYSE:ATO – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,861 shares of the utilities provider’s stock, valued at approximately $1,856,000.

Several other large investors have also recently bought and sold shares of ATO. BlackRock Inc. bought a new stake in shares of Atmos Energy during the 2nd quarter worth about $2,624,975,000. Bank of America Corp DE lifted its stake in shares of Atmos Energy by 11.0% in the 1st quarter. Bank of America Corp DE now owns 4,199,433 shares of the utilities provider’s stock worth $775,719,000 after acquiring an additional 416,933 shares during the period. Deutsche Bank AG acquired a new stake in shares of Atmos Energy in the 2nd quarter worth approximately $431,677,000. Amundi lifted its stake in shares of Atmos Energy by 40.0% in the 2nd quarter. Amundi now owns 1,823,714 shares of the utilities provider’s stock worth $314,171,000 after acquiring an additional 520,828 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Atmos Energy in the second quarter valued at approximately $276,558,000. Institutional investors and hedge funds own 90.17% of the company’s stock.

Analysts Set New Price Targets
A number of research analysts recently commented on ATO shares. Argus reiterated a “buy” rating and set a $185.00 price objective on shares of Atmos Energy in a research note on Tuesday, October 6th. Wells Fargo & Company started coverage on Atmos Energy in a report on Monday, July 13th. They set an “overweight” rating and a $200.00 target price on the stock. Truist Financial cut their target price on Atmos Energy from $179.00 to $174.00 and set a “hold” rating for the company in a research report on Thursday. Wall Street Zen lowered Atmos Energy from a “hold” rating to a “sell” rating in a research note on Monday, August 3rd. Finally, Jefferies Financial Group decreased their price target on Atmos Energy from $173.00 to $167.00 and set a “hold” rating for the company in a research note on Thursday, October 1st. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $183.00.

View Our Latest Report on Atmos Energy
Atmos Energy Price Performance
Shares of NYSE ATO opened at $167.48 on Monday. Atmos Energy Corporation has a twelve month low of $154.72 and a twelve month high of $192.51. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average of $164.05 and a two-hundred day moving average of $173.08. The company has a market capitalization of $28.30 billion, a price-to-earnings ratio of 19.94, a PEG ratio of 2.71 and a beta of 0.57.

Atmos Energy (NYSE:ATO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The utilities provider reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.08. The company had revenue of $879.06 million for the quarter, compared to analysts’ expectations of $900.82 million. Atmos Energy had a net margin of 28.50% and a return on equity of 9.67%. During the same quarter in the previous year, the company posted $1.16 EPS. Atmos Energy has set its FY 2026 guidance at 8.400-8.500 EPS. As a group, analysts expect that Atmos Energy Corporation will post 8.47 earnings per share for the current fiscal year.

Atmos Energy Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Monday, August 24th were paid a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 24th. This represents a $4.00 annualized dividend and a yield of 2.4%. Atmos Energy’s dividend payout ratio is currently 47.62%.

Insider Buying and Selling
In other Atmos Energy news, Director William Ware bought 300 shares of Atmos Energy stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average cost of $167.59 per share, for a total transaction of $50,277.00. Following the completion of the acquisition, the director owned 488 shares of the company’s stock, valued at approximately $81,783.92. This represents a 159.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.43% of the stock is currently owned by corporate insiders.

Atmos Energy Profile
(Free Report)

Atmos Energy Corporation (NYSE:ATO) is a regulated natural gas utility that distributes natural gas to residential, commercial, industrial and agricultural customers. The company also operates natural gas pipeline and storage assets, supporting the transportation and management of gas within its service areas.

Atmos Energy serves more than 3 million distribution customers across eight states, including Texas, Louisiana, Mississippi, Tennessee, Kentucky, Virginia, Kansas and Colorado. Its distribution operations include a large network of natural gas pipelines and related infrastructure, while its pipeline and storage business provides transportation and storage services primarily in Texas and Mississippi.

The company traces its history to 1906 and is headquartered in Dallas, Texas.

Featured Stories

Five stocks we like better than Atmos Energy
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Receive News & Ratings for Atmos Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atmos Energy and related companies with MarketBeat.com's FREE daily email newsletter.

A brutal sector-wide selloff crushed Lam Research even as its fundamentals held firm, and now one respected Wall Street firm has staked out a price target that would make today's buyers very happy.

Lam Research (NASDAQ:LRCX | LRCX Price Prediction) is priced at $263.94, against an analyst consensus target of $375.81. That gap works out to 42.38% of potential upside.

Lam makes the deposition and etch tools chipmakers use to stack memory layers and shape leading-edge transistors. AI spending has made it a growth story. Fiscal 2026 revenue reached $23.23 billion, up 26.02%, and Lam has now beaten EPS estimates five straight quarters.

The most aggressive call goes to C.J. Muse at Cantor Fitzgerald. His Street-high $500 target means 89.44% upside, which is close to a double.

Profit-Taking Across Chip Equipment Drove a 17% Weekly Slide Lam fell 17.22% in a single week as investors took profits across semiconductor equipment stocks. In one session during that stretch, Applied Materials (NASDAQ:AMAT) sank 7% and Lam dropped 4%, while the iShares Semiconductor ETF (NASDAQ:SOXX) slipped only 1%. Lam then lost another 4.87% in its latest session.

That pattern points to rotation out of a crowded equipment trade. Lam’s own operations remain intact. Over three months, the stock is down 13.87%, a smaller decline than the reported figure.

Bears still have numbers to point to. June-quarter operating cash flow fell 42.95% year over year, and China fell to 26% of revenue from 34% the prior quarter.

No Sell Ratings and a $500 Street-High Call Anchor the Bull Case Coverage leans mostly bullish. Of 35 analysts:

Strong Buy: 4 Buy: 25 Hold: 6 Sell: 0 Notably, no analyst has a Sell rating despite the slide.

Cantor’s thesis rests on three pillars. The firm views Lam’s etch and deposition tools as irreplaceable for HBM packaging and high-stack NAND, two bottlenecks for AI data centers. It also expects gate-all-around transistors and 3D DRAM to require more etch intensity per wafer. Finally, it points to high-margin recurring service revenue while fab utilization runs high (Cantor Fitzgerald thesis).

Management’s numbers back each pillar. NAND rose to 23% of systems revenue from 12%, advanced packaging is on track for greater than 70% growth, and customer support revenue rose 43% year over year. Management also raised its calendar 2026 WFE outlook to the “low $150 billion range.”

The next test is the September-quarter report, where Lam guided to revenue of $8.10 billion, plus or minus $400 million and EPS of about $2.15. Further out, management is aiming for mid-50% gross margins and mid-40% operating margins over the next several years. Price targets are no guarantee, and Cantor’s $500 assumes the cycle holds.

Every Toolmaker Fell, but Lam Ranks Near the Top on Upside The whole peer group sold off together.

Applied Materials fell 17.74% in a week to $409.29. Its average target of $627.83 means 53.39% upside, which beats Lam’s. The stock has earned 4 Strong Buy ratings, 29 Buy calls and 7 Hold designations.

KLA (NASDAQ:KLAC) dropped 12.82% in a week to $165.74. Its $232.77 target means 40.44% upside, a bit less than Lam’s. Analysts are more conservative here, with 10 Holds against 5 Strong Buys and 14 Buys.

ASML (NASDAQ:ASML) held up best, falling just 6.21% after reporting 55.16% revenue growth and warning that 2027 and 2028 supply will not fully meet demand. Its price of $1,641.52 versus a $2,155.32 target leaves 31.3% of upside.

Applied Materials has the biggest potential upside, and Lam is second. Lam’s discount comes from a sector-wide selloff, and it sits near the deep end of it.

Lam Still Beats the S&P 500 by a Wide Margin This Year Lam trades at $263.94. Its consensus target from 35 analysts is $375.81, means 42.38% upside. Over three months, shares fell 13.87%, while the S&P 500 rose 2.85%.

Over the full year, the picture reverses. Lam is up 54.64% year to date, compared with 11.93% for the S&P 500. The stock is valued at about 34 times forward earnings.

Lam’s Bull Case Hinges on Guidance, While China Is the Tripwire Lam Research’s outlook improves if September-quarter results land near the $8.10 billion guide and management confirms the strength in wafer fab equipment spending continues into 2027. The risk rises if China revenue keeps shrinking or hyperscaler spending cools, because a stock at 34 times forward earnings has little margin if the cycle turns.

The bull path depends on more NAND upgrades, gate-all-around adoption and HBM demand. Lam’s CFO said the industry’s current undersupply “is going to roll into next year.” The bear case comes down to export controls, falling cash flow and how quickly the stock fell this week.

Lam’s fundamentals remain intact, and the selloff hit the whole group. The consensus target looks reachable if guidance holds. Reaching $500 would require nearly everything to go right.

Contact [email protected] for any questions or corrections.

Wall Street analysts forecast that Nasdaq (NDAQ - Free Report) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year increase of 15.9%. It is anticipated that revenues will amount to $1.47 billion, exhibiting an increase of 11.7% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Nasdaq metrics that are routinely monitored and predicted by Wall Street analysts.

The average prediction of analysts places 'Net Revenues- Financial Technology' at $524.26 million. The estimate points to a change of +14.7% from the year-ago quarter.

Analysts forecast 'Net Revenues- Total Market Services, net' to reach $306.57 million. The estimate indicates a change of +1.2% from the prior-year quarter.

According to the collective judgment of analysts, 'Net Revenues- Capital Access Platforms' should come in at $633.22 million. The estimate indicates a change of +16% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Net Revenues- Financial Technology- Financial Crime Management Technology' of $103.28 million. The estimate points to a change of +23% from the year-ago quarter.

It is projected by analysts that the 'Net Revenues- Financial Technology- Regulatory Technology' will reach $122.17 million. The estimate indicates a year-over-year change of +12.1%.

Analysts' assessment points toward 'Net Revenues- Total Market Services, net- U.S. Equity Derivatives Trading' reaching $106.73 million. The estimate indicates a change of -13.9% from the prior-year quarter.

The consensus estimate for 'Net Revenues- Total Market Services, net- Cash Equity Trading (U.S. & European)' stands at $144.99 million. The estimate indicates a year-over-year change of +14.2%.

Analysts predict that the 'Cash Equity Trading - Total matched market share executed on Nasdaq?s exchanges' will reach 14.6%. Compared to the current estimate, the company reported 14.1% in the same quarter of the previous year.

Based on the collective assessment of analysts, 'Equity Derivative Trading and Clearing - Total matched market share executed on Nasdaq?s exchanges' should arrive at 28.1%. The estimate compares to the year-ago value of 28.5%.

The combined assessment of analysts suggests that 'Equity Derivative Trading and Clearing - Total industry average daily volume' will likely reach 62.52 million. The estimate is in contrast to the year-ago figure of 55.80 million.

The consensus among analysts is that 'Cash Equity Trading - Total industry average daily share volume' will reach 17.49 billion. Compared to the current estimate, the company reported 17.60 billion in the same quarter of the previous year.

Analysts expect 'Cash Equity Trading - Matched share volume' to come in at 163.43 billion. Compared to the current estimate, the company reported 158.60 billion in the same quarter of the previous year.

View all Key Company Metrics for Nasdaq here>>>

Shares of Nasdaq have experienced a change of +0.5% in the past month compared to the +1.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), NDAQ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in DICK'S Sporting Goods, Inc. (NYSE: DKS) that a securities class action placing the adequacy of the Company's SEC disclosure and risk warnings at issue has been filed on behalf of shareholders who purchased common stock between September 8, 2025 and August 24, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

DKS closed at $124.31 on August 25, 2026, down $55.02 per share, a decline of roughly 30% in a single session. Adjusted earnings came in at $3.53 per share against analyst estimates of $3.76, and Foot Locker delivered revenue of $1.73 billion versus the $1.81 billion Wall Street expected. The lead plaintiff deadline is November 3, 2026.

What the Company Disclosed

Throughout the Class Period, DKS filings and investor communications framed promotional activity in athletic footwear as a general industry condition the Company was equipped to manage. On the first quarter 2026 earnings call held May 27, 2026, management told analysts promotional activity "wasn't a major factor" and that there was "nothing on the horizon that we're particularly concerned about." At an April 2026 investor forum, management indicated investors "will see margin rate expansion" at Foot Locker.

What Plaintiffs Allege Was Missing

The complaint challenges those characterizations as incomplete. It contends the disclosures omitted that Foot Locker remained saddled with unproductive and stagnant legacy footwear silhouettes and was disproportionately dependent on launch and retro product, leaving the business exposed as inventory built up across parts of the industry. Three months after management said nothing on the horizon concerned it, the Company cut Foot Locker proforma comparable sales guidance from growth of 1.5% to 3% down to negative 2.0% to 0.0%.

Disclosure Gaps Alleged in DKS Filings and Earnings Calls

No quantification of how much of Foot Locker's assortment consisted of legacy silhouettes vulnerable to markdownsDependence on footwear launch and retro product identified as a driver of underperformance in the August 25, 2026 disclosureFull-year consolidated net sales guidance reduced to $21.9 billion to $22.2 billion, down from $22.1 billion to $22.4 billionThe action asserts the optimistic statements were not identified as forward-looking and were not accompanied by meaningful cautionary statements "Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. Here, the complaint alleges that Foot Locker's exposure to legacy footwear silhouettes was a present condition, not a hypothetical risk, at the time investors were told there was nothing on the horizon to be concerned about." -- Joseph E. Levi, Esq.

Why Generic Warnings May Not Protect

Broad cautionary language about competitive or promotional conditions does not shield statements about facts that already exist. The practical question for DKS purchasers is whether the Company's disclosure language gave the market a fair picture of what was happening inside the acquired business before the August 2026 guidance reduction.

Submit your information here or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the DKS Lawsuit

Q: When did DICK'S Sporting Goods, Inc. allegedly mislead investors? A: The Class Period runs from September 8, 2025 to August 24, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the DKS class action filed in? A: The case was filed in the United States District Court for the Western District of Pennsylvania, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the DKS lawsuit? A: The complaint names DICK'S Sporting Goods, Inc. and individual defendants including Edward W. Stack, Chairman of the Board, Lauren R. Hobart, CEO and director, and Navdeep Gupta, CFO and Executive VP.

Q: What documents do I need to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Wall Street analysts forecast that Kinsale Capital Group, Inc. (KNSL - Free Report) will report quarterly earnings of $4.95 per share in its upcoming release, pointing to a year-over-year decline of 5%. It is anticipated that revenues will amount to $478.84 million, exhibiting a decrease of 3.8% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain Kinsale Capital Group metrics that are commonly tracked and forecasted by Wall Street analysts.

It is projected by analysts that the 'Revenues- Net investment income' will reach $58.31 million. The estimate points to a change of +17.6% from the year-ago quarter.

The consensus estimate for 'Revenues- Net Earned Premiums' stands at $408.72 million. The estimate suggests a change of -0.6% year over year.

According to the collective judgment of analysts, 'Revenues- Fee Income' should come in at $11.58 million. The estimate points to a change of +12.4% from the year-ago quarter.

Analysts forecast 'Expense Ratio' to reach 21.5%. The estimate compares to the year-ago value of 21.0%.

The average prediction of analysts places 'Combined Ratio' at 80.0%. Compared to the present estimate, the company reported 74.9% in the same quarter last year.

Analysts' assessment points toward 'Loss Ratio' reaching 58.5%. The estimate is in contrast to the year-ago figure of 53.9%.

View all Key Company Metrics for Kinsale Capital Group here>>>

Kinsale Capital Group shares have witnessed a change of +2.4% in the past month, in contrast to the Zacks S&P 500 composite's +1.5% move. With a Zacks Rank #3 (Hold), KNSL is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Key Takeaways KeyCorp's Q3 earnings are projected to rise 12.2% y/y, with revenues expected to grow 7.6%.KEY's NII is expected to climb 8.4%, aided by stabilizing funding costs and steady loan demand.KEY's fee income is expected to rise 5.3%, while higher provisions and expenses may weigh on results.
KeyCorp (KEY - Free Report) is slated to announce third-quarter 2026 results on Oct. 20, before the opening bell. Following robust lending activity in the first half of 2026, loan growth appears to have moderated somewhat in the to-be-reported quarter amid persistent inflationary pressures and economic uncertainties.

Nonetheless, per the Fed’s latest data, the demand for commercial and industrial (C&I) loans, which account for a significant portion of KeyCorp’s loan portfolio, has remained resilient, supported by corporate borrowing needs and steady business activity. Consumer lending demand also provided some support. The Zacks Consensus Estimate for KEY’s third-quarter average earning assets is pegged at $174 billion, which indicates a 2.1% rise from the prior-year quarter.

Meanwhile, the interest rate environment and evolving monetary policy expectations are likely to have influenced KeyCorp’s net interest income (“NII”) performance. Stabilizing funding costs, a favorable shift in the deposit mix and steady loan demand are expected to have supported interest income generation. However, competitive deposit pricing and continued pressure on loan yields might have partially offset these benefits.

The Zacks Consensus Estimate for NII (on a fully tax-equivalent basis) is pegged at $1.29 billion, suggesting an 8.4% year-over-year increase.

Other Factors to Influence KeyCorp’s Q3 EarningsNon-Interest Income: The third quarter was challenging for the mortgage banking business as mortgage rates hovered around 7% and affordability was low. Both origination volume and refinance activity faced persistent headwinds from inventory constraints and a higher-for-longer rate regime. Given this, income from KEY’s mortgage banking business is less likely to have recorded much improvement.

The Zacks Consensus Estimate for commercial mortgage servicing fees of $53 million implies a 27.4% year-over-year decline. The consensus estimate for consumer mortgage income of $16.92 million indicates a 20.9% rise.

As the quarter witnessed a decent increase in asset inflows, the consensus estimate for KEY’s trust and investment services income of $161 million indicates a 7.3% rise from the prior-year quarter.

IPO activity remained healthy in the to-be-reported quarter. However, global bond issuance moderated following a record-setting first half, while merger and acquisition activity slowed considerably amid geopolitical uncertainties, persistent inflationary pressures and shifting interest rate expectations. These factors are likely to have weighed on investment banking activity and deal execution.

Nonetheless, elevated market volatility and robust client trading activity, driven by changing expectations surrounding artificial intelligence (AI), geopolitical tensions and the Federal Reserve’s monetary policy stance, are likely to have supported trading revenues. The Zacks Consensus Estimate for KEY’s investment banking (“IB”) and debt placement fees is pegged at $207 million, indicating a 12.5% year-over-year increase.

The consensus estimate of $79 million for service charges on deposit accounts implies 5.3% year-over-year growth. With an improvement in consumer spending in the to-be-reported quarter, the consensus mark for cards and payments income of $93 million indicates growth of 8.1%.

Overall, the consensus estimate for KeyCorp’s total non-interest income of $739 million suggests an improvement of 5.3% from the prior-year quarter.

Expenses: KeyCorp’s efforts to reorganize operations and exit unprofitable/non-core businesses have helped it save costs in the past. Also, the company’s initiatives to drive operational efficiency are likely to have curbed expense growth in the to-be-reported quarter. Yet, investments in franchises and technological upgrades are expected to have resulted in a rise in total non-interest expenses.

Asset Quality: KEY is expected to have stepped up reserve building in the third quarter, reflecting heightened credit risks stemming from the Middle East conflict, volatile oil prices, persistent inflation and elevated interest rates. Consequently, the company’s provisions for credit losses are likely to have increased in the to-be-reported quarter.

Major Q3 Development for KEYIn August, KeyCorp completed the acquisition of Clearwater Corporate Finance LLP (Clearwater UK), a UK-based middle-market IB advisory firm, marking another step in expanding the advisory business and establishing its presence in the Western European market.

Building on a collaboration between KeyBanc Capital Markets and Clearwater UK that began in 2020, the acquisition strengthens KeyCorp's middle-market M&A capabilities and enhances opportunities to serve U.S. and European corporate and private equity clients.

What the Zacks Model Predicts for KeyCorpPer our proven model, the chances of KeyCorp beating the Zacks Consensus Estimate for earnings are high this time. This is because it has the right combination of the two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better.

You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Earnings ESP: The Earnings ESP for KeyCorp is +0.44%.

Zacks Rank: The company currently carries a Zacks Rank #3.

Q3 Earnings & Sales Growth Expectations for KeyCorpThe Zacks Consensus Estimate for KEY’s earnings is pegged at 46 cents per share, which has been unchanged in the past week. The figure indicates a 12.2% rise from the prior-year quarter.

The consensus estimate for quarterly sales is pegged at $2.03 billion, indicating a year-over-year increase of 7.6%.

Other Stocks Worth ConsideringHere are a couple of other finance stocks that you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat this time around:

Associated BancCorp (ASB - Free Report) is scheduled to announce third-quarter 2026 results on Oct. 22. The company currently has a Zacks Rank #3 and an Earnings ESP of +1.71%.

Quarterly earnings estimates for ASB have been unchanged at 76 cents per share over the past week.

The Earnings ESP for Ameriprise Financial (AMP - Free Report) is +0.35% and it carries a Zacks Rank of 3 at present. The company is slated to report third-quarter 2026 results on Oct. 29. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the past seven days, the Zacks Consensus Estimate for AMP’s quarterly earnings has been unchanged at $11.60 per share.

Vontobel Holding Ltd. cut its stake in shares of Cognex Corporation (NASDAQ:CGNX – Free Report) by 53.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,785 shares of the scientific and technical instruments company’s stock after selling 35,942 shares during the period. Vontobel Holding Ltd.’s holdings in Cognex were worth $1,928,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CGNX. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Cognex in the 2nd quarter worth $26,000. Rakuten Securities Inc. bought a new position in shares of Cognex during the second quarter valued at about $32,000. Transamerica Financial Advisors LLC bought a new position in shares of Cognex during the second quarter valued at about $32,000. Mather Group LLC. lifted its position in shares of Cognex by 81.3% during the third quarter. Mather Group LLC. now owns 446 shares of the scientific and technical instruments company’s stock valued at $27,000 after purchasing an additional 200 shares in the last quarter. Finally, Elevation Wealth Partners LLC boosted its holdings in Cognex by 635.4% during the second quarter. Elevation Wealth Partners LLC now owns 478 shares of the scientific and technical instruments company’s stock worth $35,000 after purchasing an additional 413 shares during the last quarter. 88.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes
A number of equities research analysts have issued reports on CGNX shares. Zacks Research downgraded shares of Cognex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Needham & Company LLC reissued a “buy” rating and set a $80.00 target price on shares of Cognex in a research report on Tuesday, September 15th. Truist Financial set a $74.00 target price on shares of Cognex and gave the stock a “hold” rating in a research report on Monday, October 5th. Weiss Ratings upgraded Cognex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald upped their target price on Cognex from $76.00 to $84.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $75.57.

Read Our Latest Stock Report on CGNX
Cognex Stock Performance
Shares of CGNX stock opened at $53.99 on Monday. The stock has a market capitalization of $9.08 billion, a P/E ratio of 52.42 and a beta of 1.48. The firm’s 50 day moving average is $61.08 and its 200 day moving average is $61.67. Cognex Corporation has a 12 month low of $34.60 and a 12 month high of $72.88.

Cognex (NASDAQ:CGNX – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The scientific and technical instruments company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. Cognex had a net margin of 16.05% and a return on equity of 13.50%. The business had revenue of $291.26 million during the quarter, compared to analyst estimates of $292.10 million. During the same period in the previous year, the business earned $0.25 EPS. Cognex’s revenue was up 16.9% compared to the same quarter last year. Cognex has set its FY 2026 guidance at 1.640-1.680 EPS and its Q3 2026 guidance at 0.500-0.540 EPS. On average, equities analysts predict that Cognex Corporation will post 1.68 EPS for the current year.

Cognex Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th were issued a $0.0850 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Thursday, August 20th. Cognex’s dividend payout ratio (DPR) is presently 33.01%.

Cognex Company Profile
(Free Report)

Cognex Corporation (NASDAQ: CGNX) develops machine vision products and technologies that help businesses automate manufacturing, logistics and other industrial processes. Its systems enable machines to inspect, identify, measure and guide products, components and materials with limited human intervention.

The company’s product portfolio includes industrial vision cameras, vision sensors, image-based barcode readers, three-dimensional vision systems and software for image processing and analysis.

Read More

Five stocks we like better than Cognex
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Want to see what other hedge funds are holding CGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cognex Corporation (NASDAQ:CGNX – Free Report).

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.

American Eagle Outfitters (AEO - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this teen clothing retailer have returned +19.4% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Retail - Apparel and Shoes industry, to which American Eagle belongs, has gained 12% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, American Eagle is expected to post earnings of $0.49 per share, indicating a change of -7.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.7% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $2.24 points to a change of +49.3% from the prior year. Over the last 30 days, this estimate has changed +3.2%.

For the next fiscal year, the consensus earnings estimate of $1.89 indicates a change of -15.2% from what American Eagle is expected to report a year ago. Over the past month, the estimate has changed -0.5%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for American Eagle.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of American Eagle, the consensus sales estimate of $1.46 billion for the current quarter points to a year-over-year change of +6.8%. The $5.86 billion and $6.07 billion estimates for the current and next fiscal years indicate changes of +6.6% and +3.5%, respectively.

Last Reported Results and Surprise HistoryAmerican Eagle reported revenues of $1.38 billion in the last reported quarter, representing a year-over-year change of +7.5%. EPS of $0.79 for the same period compares with $0.45 a year ago.

Compared to the Zacks Consensus Estimate of $1.37 billion, the reported revenues represent a surprise of +0.99%. The EPS surprise was +276.19%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

American Eagle is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about American Eagle. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

93% of utilities say significant data and intelligence investments have enabled at least two additional use cases beyond their original purpose, including 47% that report four or more.Load growth is utilities’ top grid stressor at 43%, followed by rising customer expectations at 36%.Over the next three years, utilities are prioritizing enterprise integration (28%), executive decision support (23%) and workflow automation (20%).
LIBERTY LAKE, Wash., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), the intelligent infrastructure provider for modern energy and water management, today released its 2026 Resourcefulness Report: Data Analytics and the Intelligent Grid—How Do Utilities Turn Intelligence into Action? The findings show electric utilities have built a strong foundation of data and intelligence capabilities, with the next opportunity centered on connecting those capabilities more consistently to everyday operational decisions.

Utilities are already putting intelligence to work across core grid operations. Near real-time edge data is informing decisions across wildfire risk, outage detection and restoration, load and demand management, and fault location and isolation. Operationalized analytics are delivering the greatest value in outage management and restoration and predictive maintenance, tied at 33%, followed by workforce efficiency at 30% and peak-load management at 29%.

The study uncovered that while intelligence is broadly used, at most utilities it isn’t fully embedded into everyday operations. A total of 86% of utilities use AMI data enterprise-wide or in specific workflows; however, only 41% say it is fully embedded and scalable across daily workflows. And while 93% are confident data insights are changing decisions, just 54% report strong feedback loops confirming that impact. Technical integration and lack of automation remain the leading barriers to broader operationalization.

“Utilities have made tremendous progress building the data and intelligence capabilities they need to manage an increasingly complex grid,” said Marina Donovan, vice president of global marketing, ESG and public affairs at Itron. “As load growth and other pressures accelerate, the opportunity now is to connect that intelligence to the decisions utilities make every day. At Itron, we’re helping utilities create virtual eyes on the grid, giving them greater visibility into changing conditions, reducing guesswork and turning intelligence into action at scale, strengthening reliability, resilience and affordability.”

Key findings:

Existing investments are multiplying in value: 93% of utilities say major data and intelligence investments have enabled at least two additional use cases beyond their original purpose, while 58% deliberately select data and intelligence investments for their ability to support multiple current and future use cases.Grid intelligence is already supporting critical operations: 59% say near real-time edge intelligence is fully operational, with utilities applying it to areas including wildfire and vegetation risk, outage detection and restoration, load management and fault location.Analytics are delivering value where utilities need it most: Outage management and restoration and predictive maintenance lead the areas where operationalized intelligence is delivering the greatest value, at 33% each, followed by workforce efficiency at 30% and peak-load management at 29%.The next phase is connecting intelligence to action: Technical integration is the leading obstacle to using data for decision-making at 53%, followed by lack of automation at 47% and data quality at 44%. Looking ahead, enterprise integration is utilities' leading three-year priority for operationalizing intelligence at 28%, followed by executive decision support at 23% and workflow automation at 20%. “Utility modernization doesn’t always require starting from scratch,” added Donovan. “When infrastructure and data can support multiple use cases, utilities can build on investments already in place as their needs evolve. Connecting intelligence across the grid edge, field, control room and enterprise can help utilities respond faster to emerging pressures while creating more value from their technology investments.”

The full 2026 Itron Resourcefulness Report explores how utilities are advancing intelligence across four stages of the utility workflow: intelligent infrastructure, data to decisions, daily operations and the operationalized grid.

To download the full report and companion research, visit www.itron.com/resourcefulness-report

Research Methodology

The 2026 Resourcefulness Report research was conducted in partnership with Blackstone Group. A total of 700 online surveys were completed in June 2026 among electric utility executives in the United States, Canada, Australia, New Zealand, Sweden, Norway and Finland. Respondents were mid-level managers or higher with input on decision-making in electricity utility operations. The sample included 400 respondents in the United States, 100 in Canada, 100 in Australia and New Zealand and 100 across the Nordic countries of Sweden, Norway and Finland.

About Itron

Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com.

Itron® and the Itron Logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

Itron, Inc.

Alison Mallahan
Senior Manager, Corporate Communications
509-891-3802
[email protected]

Paul Vincent
Vice President, Investor Relations
512-560-1172
[email protected]

Fifth Third Bancorp (FITB - Free Report) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.67%. A quarter ago, it was expected that this company would post earnings of $0.98 per share when it actually produced earnings of $1.02, delivering a surprise of +4.08%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Fifth Third Bancorp, which belongs to the Zacks Banks - Major Regional industry, posted revenues of $3.28 billion for the quarter ended September 2026, missing the Zacks Consensus Estimate by 1.74%. This compares to year-ago revenues of $2.3 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Fifth Third Bancorp shares have added about 7.6% since the beginning of the year versus the S&P 500's gain of 11.9%.

What's Next for Fifth Third Bancorp?While Fifth Third Bancorp has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Fifth Third Bancorp was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.20 on $3.41 billion in revenues for the coming quarter and $4.16 on $12.87 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Major Regional is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

KeyCorp (KEY - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2026. The results are expected to be released on October 20.

This company is expected to post quarterly earnings of $0.46 per share in its upcoming report, which represents a year-over-year change of +12.2%. The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level.

KeyCorp's revenues are expected to be $2.03 billion, up 7.6% from the year-ago quarter.

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for people with obstructive sleep apnea (OSA) to provide greater comfort and choice in therapy1, the AirTouch F40 helps address key factors that can influence long-term adherence.

OSA is a growing health challenge, affecting more than one billion people worldwide.2 In the U.S., an estimated 61 million people have OSA, a number projected to rise to nearly 77 million by 2050.3 CPAP therapy remains the gold standard treatment for OSA4, and for those on CPAP, mask comfort and fit can play an important role in how people stay engaged with therapy over time.

AirTouch F40 brings Resmed’s proprietary ComfiSoft™ fabric cushion to a minimalist design that is intended to adapt to a person’s face as they move throughout the night. Because comfort preferences vary from person to person, expanding mask choice helps give people another option to meet their individual needs. The mask’s wide fit range and intuitive design are also intended to make it easier for healthcare providers to help patients find a comfortable fit and support them throughout therapy.

AirTouch F40 builds on Resmed’s growing portfolio of fabric-based mask technology and reflects the company’s commitment to delivering more personalized experiences that support patients throughout their therapy experience. Resmed has seen encouraging outcomes across its fabric mask portfolio, including a 6% increase in 90-day compliance among users of a fabric-cushioned mask compared with users of a silicone-cushioned mask.5

“AirTouch F40 is one example of how we're continuing to redefine what's possible to create more comfortable and personalized therapy experiences,” said Justin Leong, Chief Product Officer at Resmed. “By building on the success of AirFit F40™ and introducing a new fabric option, we're giving people greater flexibility to choose the mask that works best for them. That's the kind of innovation that can help more people start and stay on CPAP therapy.”

Key features of AirTouch F40 include:

Designed to fit and move with the user: AirTouch F40 is designed to fit 96% of people6 with a minimalist design that adapts to the face as people move throughout the night.Brings fabric comfort to the full-face experience: The ComfiSoft fabric cushion features soft, breathable, and moisture-wicking fabric7 designed for comfort against the skin.A familiar platform for existing AirFit F40 users: The interchangeable cushion allows current AirFit F40 users to try the fabric cushion without changing mask systems or being resized or refitted. Connected support throughout therapy
AirTouch F40 is part of Resmed’s connected sleep health platform, bringing together devices, digital tools and provider support to create a more connected therapy experience and help people stay engaged over time.

Through myAir™, Resmed’s patient engagement app, people can track their therapy progress, access personalized guidance and receive ongoing support throughout their therapy experience. This includes upcoming features such as Equipment Care, a tool that is designed to encourage patients to take action and stay engaged in managing their CPAP equipment. Healthcare providers can use AirView™, Resmed’s remote monitoring platform, to view therapy insights and support patients between appointments. When used alongside AirView, myAir has been shown to improve therapy compliance from 70% to 87%.8

AirTouch F40 will be available in the U.S. beginning October 28, 2026. For more information, visit https://www.resmed.com/en-us/health-professionals/campaigns/airtouch-f40/

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.

For Media

Keleigh Andrus
[email protected]
[email protected]

For Investors

Salli Schwartz
[email protected]
[email protected]

1 Resmed external crossover study comparing AirTouch F40 mask against other Resmed and third-party masks. n=36. Data on file, ID: A5768170.
2 Benjafield AV, et al. Lancet Respir Med. 2019 Aug; 7(8):687-698.
3 Boers E, et al. Lancet Respir Med. 2025;13(12):1078–1086.
4 Patil SP et al. J Clin Sleep Med. 2019 Feb 15;15(2):301-334.
5 Resmed analysis of 90-day PAP compliance among U.S. patients using AirView™ and myAir™, comparing AirTouch™ N30i and AirFit™ N30i. Data on file, ID: A5707362.
6 Internal Resmed analysis of projected cushion fit per region. Data on file, ID: A5756043.
7 Resmed internal testing of the moisture-wicking properties of fabric. Data on file, ID: A5636924.
8 Malhotra et al., CHEST. 2018; 153(4): 843–850.

Key Takeaways Comcast is expected to report Q3 revenues of $29.35 billion and earnings of 98 cents per share.Broadband pressure, softer theme park demand and Peacock's post-World Cup slowdown may weigh on results.Universal's box office success offers support, while elevated capital spending pressures free cash flow.
Comcast (CMCSA - Free Report) is scheduled to report its third-quarter 2026 results on Oct. 22.

The Zacks Consensus Estimate for third-quarter earnings is pegged at 98 cents per share, down by a penny over the past 30 days. The figure indicates a 12.5% decrease from the year-ago quarter’s reported figure.

The consensus mark for revenues is pegged at $29.35 billion, indicating a 5.92% decrease from the year-ago quarter’s reported figure.

CMCSA’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 7.32%.

Let us see how things are shaping up for the upcoming announcement.

Factors to ConsiderThe quarter is likely to have reflected a business in transition, with connectivity pressure and softer theme park demand weighing on gains in streaming and film. Comparisons are expected to have been clouded by the May 31 sale of Sky’s German operations and the planned tax-free spin-off of NBCUniversal and Sky, announced on June 29.

Connectivity & Platforms is expected to have remained the key drag. In the second quarter, domestic broadband revenues fell 5.5% as Comcast held rates steady and migrated customers to lower price points, while Residential EBITDA margin contracted 160 basis points to 37.7%. Management guided for only modest improvement from the third quarter as free wireless lines converted to paying relationships, implying broadband revenues likely stayed under pressure. Wireless momentum, after a record 448,000 line additions, is expected to have continued, though free-line promotions are likely to have diluted revenue per line. Business Services, which grew revenues 3.7% last quarter, is expected to have offered support, aided by network expansions such as multi-gigabit availability in Beaufort and Edisto, SC, in September.

In Media, Peacock is likely to have benefited from price increases of $1-$3 per month across plans, effective Aug. 18 for new subscribers, alongside the August beta launch of a membership rewards program. However, Peacock’s maiden $189 million second-quarter profit was aided by the FIFA World Cup, which added $440 million of incremental Media revenues, and the event’s July conclusion is likely to have tempered growth.

Studios is expected to have been a bright spot. Universal became the first studio to cross $4 billion in 2026 global box office by August, powered by The Odyssey, Christopher Nolan’s biggest opening ever, and Minions & Monsters, which debuted at No. 1. Higher marketing and production costs are likely to have partly offset these gains.

Theme Parks is likely to have stayed soft, as Orlando attendance weakened in June and remained pressured into the third quarter, while Osaka faced travel headwinds. Universal Kids Resort, opened July 1 in Frisco, TX, is expected to have added revenues but also start-up costs.

Capital expenditures are expected to have stayed elevated after rising 8.3% to $2.9 billion last quarter, with Connectivity & Platforms spending up 19.9%, pressuring free cash flow. The buyback pause announced on June 29 is likely to have limited earnings support.

What Our Model SaysAccording to the Zacks model, the combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.

Comcast currently has an Earnings ESP of -0.09% and a Zacks Rank #5 (Strong Sell). You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Stocks to ConsiderHere are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.

PEOPLES BANCORP (PEBO - Free Report) has an Earnings ESP of +1.09% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

PEOPLES BANCORP shares have gained 22.3% year to date. PEOPLES BANCORP is scheduled to report its third-quarter 2026 results on Oct. 20.

ATI INC (ATI - Free Report) has an Earnings ESP of +1.09% and sports a Zacks Rank #1.

ASE Technology shares have surged 61.7% year to date. ATI INC is set to report its third-quarter 2026 results on Oct. 29.

BP (BP - Free Report) has an Earnings ESP of +7.29% and flaunts a Zacks Rank #1 at present.

BP shares have gained 44.6% in the year-to-date period. BP is set to report third-quarter 2026 results on Oct. 30.

Shares of Lululemon (LULU -0.45%) have been beaten down over the past few years, but this week the stock popped more than 5% at times. A rotation out of tech stocks into consumer discretionary is the most likely reason for the gain. The rise, albeit small, is welcomed by investors who have watched the stock plummet by more than 75% over the past five years.

LULU Lululemon Athletica Inc.$96.66-$0.44 (-0.45%)

NASDAQ · As of 9:37 AM ET 10/19/26

The apparel company is facing a slew of problems. From declining revenue and comparable sales to a cut in full-year guidance and reputational damage, the challenges are vast for the new CEO, Heidi O'Neill, who took the helm just a month ago. In the second quarter of 2026, revenue fell 4% to $2.4 billion while comparable sales were down 9%.

On the positive side, Lululemon carries no debt on its balance sheet and has about $1.4 billion in cash. The company is also buying back shares.

Image source: The Motley Fool.

So does that mean this small jump in the stock is worth buying into? Ultimately, I don't think so, or at least not right at the moment. The stock is definitely cheap. Its trailing P/E ratio is in the single digits, and forward is about 10 times earnings. Yet, it's inexpensive for a reason. Sales continue to fall, and I need to see O'Neill implement a turnaround strategy that can truly revive the brand over the long term.

I do believe there's hope for Lululemon, but it's going to take some time for this brand to reinvent itself.

Catie Hogan has no position in any of the stocks mentioned. The Motley Fool recommends Lululemon Athletica Inc. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Arthur J. Gallagher & Co. today announced the acquisition of Melbourne, Victoria-based Intelligent Communications Experiences. Terms of the transaction were not disclosed.

Intelligent Communications Experiences helps businesses in Australia develop and deliver digital employee communications. The Intelligent Communications Experiences team, led by Chris Cansfield, Steve Mann, Glyn Wallens and Kevin McDougall, will operate under the direction of Graham Campbell, head of Gallagher's employee benefits and HR consulting operations in Australia and New Zealand.

"Intelligent Communications Experiences brings us a talented consulting team and broadens our employee communications capabilities in Australia," said J. Patrick Gallagher, Jr., Chairman and CEO. "I am very pleased to welcome Chris, Steve, Glyn, Kevin and their associates to Gallagher."

Arthur J. Gallagher & Co. (NYSE:AJG), a global insurance brokerage, risk management and consulting services firm, is headquartered in Rolling Meadows, Illinois. Gallagher provides these services in approximately 130 countries around the world through its owned operations and a network of correspondent brokers and consultants.

Investor Relations: Sara Walsh, CFA                 Media Relations: Paul Day
630-285-3593 / [email protected]               630-285-5946 / [email protected]

SOURCE Arthur J. Gallagher & Co.

 | Source: MKS Inc.

ANDOVER, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that it has entered into a definitive agreement to sell its Ophir® Optics business to TTM Technologies, Inc. (“TTM”) in an all-cash transaction for $650 million, subject to customary closing adjustments. The purchase price represents an estimated multiple of over 18x projected FY 2026 Adjusted EBITDA for the Ophir Optics business.

The Ophir Optics business provides high-precision infrared thermal imaging and laser optics solutions to customers in MKS’ Specialty Industrial market, serving defense, security and industrial applications. 

TTM is a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced interconnect products, including printed circuit boards and substrates.

“The Ophir Optics business highlights how we can apply our broad technology capabilities to serve attractive opportunities outside our core Semiconductor and Electronics & Packaging markets. This transaction represents an opportunity for MKS to capitalize on the value we’ve created with the Ophir Optics business and further strengthen our balance sheet,” said John T.C. Lee, President and Chief Executive Officer, MKS Inc. “We believe TTM is well positioned to support this business in its next phase of growth.”

This transaction does not include the MKS Ophir Instruments laser characterization business, which operates separately from Ophir Optics, or the sale of the Ophir brand. Ophir Instruments provides laser power measurement and beam profiler solutions core to our photonics solutions portfolio, and there will be no impact on the products, services, and support MKS provides to its Ophir Instruments customers.

The transaction is expected to close in the second quarter of 2027, and is subject to customary closing conditions, including certain regulatory approvals and certain governmental consents and permits.

J.P. Morgan Securities LLC is serving as exclusive financial advisor and Herzog Fox & Neeman is serving as lead legal advisor to MKS in connection with this transaction.

About MKS Inc.

MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

Use of Non-GAAP Financial Results

This press release references forward-looking Adjusted EBITDA of the Ophir Optics business, a financial measure that is not in accordance with U.S. generally accepted accounting principles (a “Non-GAAP financial measure”). This Non-GAAP financial measure should be viewed in addition to, and not as a substitute for, MKS’ reported results under U.S. generally accepted accounting principles (“GAAP”), and may be different from Non-GAAP financial measures used by other companies. In addition, this Non-GAAP financial measure is not based on any comprehensive set of accounting rules or principles. MKS management believes the presentation of this Non-GAAP financial measure is useful to investors for comparing prior periods and analyzing ongoing business trends and operating results.

MKS is not providing a quantitative reconciliation of forward-looking Adjusted EBITDA to GAAP net income of the Ophir Optics business because we are unable to estimate with reasonable certainty the ultimate timing or amount of certain significant items without unreasonable efforts. These items include, but are not limited to, amortization of intangible assets, restructuring and other expense, goodwill and intangible asset impairments, excess and obsolescence inventory charges, and the income tax effect of these items. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the relevant period.

Safe Harbor for Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the future financial performance, business prospects and growth of MKS, and the expected time of closing of the transaction. These statements are only predictions based on current assumptions and expectations. Any statements that are not statements of historical fact (including statements containing the words “will,” “projects,” “intends,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “forecasts,” “continues” and similar expressions) should be considered to be forward-looking statements. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Among the important factors that could cause actual events to differ materially from those in the forward-looking statements that we make are the failure or inability of TTM or MKS to meet the closing conditions or to otherwise consummate the transaction, the ability to realize the expected benefits of the transaction, and the other important factors described under the heading “Risk Factors” in Part I, Item 1A of MKS’ Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Quarterly Reports on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise, even if subsequent events cause our views to change, after the date of this press release.

Investor Relations Contact:
Paretosh Misra
Vice President, Investor Relations
MKS Inc.
Telephone: (978) 284-4705
Email: [email protected]

Press Relations Contacts:
Bill Casey
Vice President, Marketing
MKS Inc.
Telephone: (630) 995-6384
Email: [email protected]

Kerry Kelly, Partner
Kekst CNC
Email: [email protected]

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

, /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney disease if left untreated.

Published in the journal Hypertension, a publication of the American Heart Association, the findings suggest that changing the diagnostic threshold for PA would double the detection rate, identifying thousands of high-risk patients who may otherwise be undiagnosed and untreated.

Researchers from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School conducted the study, based on deidentified results of lab tests performed by Quest on over 60,449 patients in the United States.

Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood. High blood pressure is a defining feature of the condition, though affected individuals may have other common symptoms like headaches or muscle cramps. If left untreated, several complications can occur.

In 2025, the Endocrine Society published guidelines that recommend screening for PA for all patients with high blood pressure and included criteria for diagnosing PA. However, the new study suggests these guidelines are "overly restrictive," with laboratory cutoffs for aldosterone levels that detect only the most advanced cases of the disease. The guideline update also recommends plasma renin activity (PRA), a blood test that measures the conversion of renin in the kidneys, as the initial screening test.

When the researchers applied the 2025 criteria (PRA ≤1 ng/mL/h, aldosterone levels ≥7.5 ng/dL, ARR > 15) to the patient cohort, only 13.0% of individuals were identified as positive for PA. However, a broader, "permissive" set of criteria (PRA ≤1 ng/mL/h, aldosterone levels >5 ng/dL, without an ARR requirement) applied to the same cohort identified approximately twice as many patients, 26.2%, with PA. Additionally, clinical conditions consistent with PA such as hypertension, hypokalemia, and atrial fibrillation (based on insurance claim billing), were enriched among patients categorized as positive for PA by the more permissive laboratory cutoffs.

Among patients identified by the more permissive criteria, a PRA score of < 0.5 ng/mL/hr had 1.27 times higher odds of having hypertension compared to those with a higher (or normal) PRA (P < 0.0001). Patients with a PRA of < 0.25 ng/mL/hr had 2.62 times higher odds of having atrial fibrillation (P = 0.0032). 79.0% of the additional patients identified by permissive criteria were missed by the 2025 criteria because they had aldosterone levels between 5 and 7.5 ng/dL, below the ES cutoff, while approximately one in five had aldosterone levels that met the ES criteria but did not meet the ARR threshold.

The findings suggest the 2025 guidelines may guide physicians to identify only the more advanced forms of the disease and that primary aldosteronism should be viewed as a spectrum rather than a positive or negative diagnosis of disease. Earlier detection using more relaxed diagnostic criteria may help clinicians identify and intervene with care with potential to prevent long-term cardiovascular complications.

"Our findings demonstrate that current international clinical guidelines for diagnosing primary aldosteronism are optimized to identify advanced disease but may be less sensitive for earlier or milder forms of PA," said lead author Marco Marcelli, MD, a board-certified endocrinologist and Medical Director at Quest Diagnostics. "Some patients with PA spend years on a diagnostic journey before learning their hypertension, headaches and other symptoms are due to a highly treatable condition. More expansive screening and diagnostic criteria may help the medical community to quickly identify these individuals hiding in plain sight before irreversible heart damage and other adverse outcomes have occurred."

The study's strengths include its large patient cohort and its limitations include its retrospective design and lack of confirmatory testing.

Primary aldosteronism is a serious condition that affects as many as 5-10% of adults with high blood pressure. Up to 25-30% of patients with hypertension may be diagnosed with PA if the criteria identified by the Quest group will eventually be confirmed in prospective studies. High blood pressure is widely prevalent in the U.S., affecting nearly half of all adults (almost 120 million individuals). For many years, PA was considered uncommon; however, a 2024 study published in Hypertension by researchers at Quest Diagnostics shows PA is likely under-detected.

About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

SOURCE Quest Diagnostics

Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows  | Source: PacBio

MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.

The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration.

“This collaboration reflects a shared focus on making high-quality genomic data more accessible and useful across research and development, while creating a foundation for continued innovation in health,” said Stephen Gillett, Chairman and CEO of Verily Health. “Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need.”

“PacBio HiFi sequencing offers our customers the most complete and highest quality data available, which is ideal for training AI models where the input determines the success of the output” said Mark Van Oene, President and CEO of PacBio. “Through this collaboration with Verily Health, we are building a path to turn richer biological data into AI-ready data at scale to ultimately help researchers get more from both their sequencing and their models.”

Verily Pre provides the foundation to build, deploy and scale intelligent applications across healthcare and life sciences. Under the collaboration, Verily Health will configure Pre Workbench to connect PacBio sequencing workflows, acting as the secure governed research environment for the aggregation, analysis, and curation of HiFi genomic datasets. The companies also plan to use the Verily Pre trusted agentic environment (TAE) to run model training and inference, enabling researchers to explore deeper, longitudinal genomic datasets and support their workflows. Over the course of the multi-year collaboration, PacBio and Verily Health plan to expand the integration to support increasingly large and complex long-read programs across research organizations, biopharma and population genomics. The companies envision a common infrastructure that can scale with increasingly large and complex long-read programs, supporting multimodal research and AI development across biopharma, clinical institutions, population genomics and other areas of precision health.

About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.comand follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

About Verily Health Inc.
At the intersection of technology, data science, and healthcare, Verily Health transforms complex health data into trusted intelligence, enabling health solutions that are more personal, predictive, and precise.

Verily’s flagship Governed Health Intelligence platform, Verily Pre, enables healthcare organizations to responsibly govern, model, and securely activate their protected health data at scale, deploying intelligence with the scientific rigor, oversight, and auditability needed for healthcare.

For more information about Verily Health, please visit verily.com

Disclaimer:
The Verily Pre platform is not a medical device and has not been evaluated by the FDA. Customers developing Software as a Medical Device (SaMD) are solely responsible for regulatory compliance.

Forward looking statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and Verily Health; plans to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform to create AI-ready clinic-genomic datasets; making genomic data more accessible and usable to power future biomedical AI application and create a foundation for continued innovation in health; impact in finding new answers for neurology, oncology, rare disease, and other areas of critical unmet need; building a path to turn richer biological data into AI-ready data; Verily Health configuring Pre Workbench as secure governed research environment; the use of TAEs to run model training and inference; developing a common infrastructure capable of supporting increasingly large and complex long-read programs; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using , and collaborating with third parties to develop, new technologies; potential product performance, interoperability and quality issues; potential regulatory issues relating to the development and use AI technologies; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Media Contacts

PacBio
Investors: 
[email protected]
Media:
[email protected]

Verily Health
Laurie Ferguson
[email protected] 

Cleveland-Cliffs (CLF - Free Report) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to a loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this mining company would post a loss of $0.21 per share when it actually produced a loss of $0.2, delivering a surprise of +4.76%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Cleveland-Cliffs, which belongs to the Zacks Steel - Producers industry, posted revenues of $5.61 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 0.56%. This compares to year-ago revenues of $4.73 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Cleveland-Cliffs shares have lost about 8.7% since the beginning of the year versus the S&P 500's gain of 11.9%.

What's Next for Cleveland-Cliffs?While Cleveland-Cliffs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Cleveland-Cliffs was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.37 on $5.47 billion in revenues for the coming quarter and $0.10 on $21.13 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Steel - Producers is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, SSAB (SSAAY - Free Report) , has yet to report results for the quarter ended September 2026.

This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

SSAB's revenues are expected to be $2.91 billion, up 20.6% from the year-ago quarter.

 | Source: Altimmune, Inc

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability

Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide

GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

Data being presented will include results from 48-week IMPACT Phase 2b analyses in metabolic dysfunction-associated steatohepatitis (MASH) which showed that treatment with pemvidutide achieved concurrent reductions in two non-invasive markers of fibrosis, liver stiffness and ELF score, as well as liver fat and alanine aminotransferase (ALT) compared to placebo. These concordant changes across multiple non-invasive tests provide a more robust picture of treatment response than an individual measure. Separate IMPACT data showed that gastrointestinal adverse events were mild to moderate, with no severe gastrointestinal treatment-emergent adverse events reported. Treatment discontinuations due to adverse events were lower with pemvidutide than placebo, with a greater proportion of pemvidutide-treated patients completing study treatment despite no dose titration.

New preclinical data also showed a significant reduction in mean alcohol intake with pemvidutide in a hamster model, supporting further clinical investigation of pemvidutide in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).

Altimmune will also have an Exhibit Booth at the meeting.

Details of the presentations are as follows:

Oral Presentations:

Abstract Title: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model Session: Industry Review ShowcaseDate/Time: Saturday, November 7, 2026, 8:15 a.m. MTPresenter: John J. Suschak Abstract Title: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis Session: Clinical Trial Pipeline for MASH 2026Date/Time: Sunday, November 8, 2026, 11:45 a.m. – 12:00 p.m. MTPresenter: Dr. Naim Alkhouri Poster Presentation:

Abstract Title: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial Session: MASLD/MASH TherapeuticsDate/Time: Saturday, November 7, 2026, 1 p.m. - 2 p.m. MTPresenter: Dr. Mazen Noureddin A copy of the oral presentations and posters will be accessible on the Events section of the Altimmune website following the meeting.

Exhibit Booth

Altimmune will showcase its pipeline in a newly designed display in the exhibit hall at the Colorado Convention Center, open November 6, 2026, from 5:00 to 6:30 p.m. MT and November 7-8, 2026, from 9:30 a.m. to 5:00 p.m. MT.

The Booth will feature information on pemvidutide, along with information on the Company's actively enrolling PERFORMA Phase 3 trial of pemvidutide in patients with MASH. Altimmune medical affairs staff will be on-site throughout the meeting to engage with conference attendees.

About Pemvidutide

Pemvidutide is an investigational novel peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that effects reductions in liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

About the IMPACT Phase 2b Study
The randomized, placebo-controlled, double-blind IMPACT Phase 2b trial (NCT05989711) enrolled 212 participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 or F3, with and without diabetes. Study participants were randomized 1:2:2 to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg or placebo for 48 weeks. The primary efficacy endpoints, measured at 24 weeks, were MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH. Secondary endpoints included non-invasive tests of fibrosis and weight loss measured at 24 and 48 weeks.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
[email protected]

Media Contact:
Real Chemistry
[email protected]

Bitmine owns 4.9% of the total ETH coin supply of 122.1 million

Bitmine is 99% of the way to the 'Alchemy of 5%' in just 15 months

Bitmine released Chairman's Message on October 7 titled "Crypto Bull Underway — This Cycle Likely the Largest"

Bitmine was added to the Russell 1000 Large-cap index on June 26, 2026

Bitmine's Series A Preferred Stock is trading on the NYSE under the symbol BMNP

Bitmine has 5,067,309 staked ETH, representing $12 billion at $2,365 per ETH. MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors

Bitmine owns $74 million of Eightco (NASDAQ: ORBS), now one of the only publicly listed equities in the world to provide investors indirect exposure to OpenAI

Bitmine Crypto + Total Cash Holdings & Marketable Securities + "Moonshots" total $15.1 billion, including 6.04 million ETH tokens, total cash & marketable securities of $582 million, and other crypto holdings

Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH

, /PRNewswire/ -- (NYSE: BMNR) Bitmine Immersion Technologies, Inc. ("Bitmine" or the "Company"), a Bitcoin and Ethereum Network company with a focus on the accumulation of crypto for long term investment, today announced Bitmine crypto + total cash & marketable securities + "moonshots" holdings totaling $15.1 billion.

BITMINE: Achievements in first year of operations

Chairman's Message: Crypto Bull Underway

STAKING: BMNR now staking over 5 million ETH as of Oct 18, 2026

"The risk appetite of investors contracted in the past few weeks fueled by the worrying combination of AI funding and AI model safety; escalating US-Iran war activity; anxiousness in front of US midterm elections and generally rising bond yields around the world. This has triggered a selloff in AI stocks including semis and memory stocks, and has further led to selloffs in the Korean and Taiwan markets, both of which are dominated by semis and memory stocks," stated Thomas "Tom" Lee, Chairman of Bitmine.

"Crypto is widely held in the US, Korea and Taiwan. So naturally, when investors in those regions de-risk, this creates spillover pressures in crypto markets. In the past, whenever fundamentals remain resilient and strong, while price declines, these have historically been attractive risk/reward opportunities. And given crypto's positive exposure to both modernizing global financial system rails and to agentic-AI, we believe this will again prove to be the case," continued Lee.

As of October 18, 2026 at 3:00pm ET, the Company's crypto holdings are comprised of 6,041,481 ETH at $2,365 per ETH (per CoinbaseNASDAQ: COIN), 215 Bitcoin (BTC), $180 million stake in Beast Industries, $74 million stake in Eightco Holdings (NASDAQ: ORBS) ("moonshots") and total cash & marketable securities of $582 million. Bitmine's ETH holdings are 4.9% of the ETH supply (of 122.1 million ETH).

"We believe Bitmine is positioned to outperform the crypto bull market that we expect to be coming, as the company has strengthened its competitive position over the past year in the midst of a crypto winter (bear market)," continued Lee.

"Over the past week, we acquired 12,535 ETH. Bitmine's track record of consistent buying of crypto is unmatched by any public company in the world. Bitmine has bought ETH each and every week since the inception of the ETH Treasury Strategy on June 30, 2025," stated Lee.

On October 7, Bitmine released its latest Chairman's message titled "Crypto Bull Underway — This Cycle Likely the Largest." The presentation is available at the Bitmine website (presentation link).

Earlier in 2026, Bitmine launched MAVAN (the Made in America VAlidator Network), the institutional-grade staking platform. While MAVAN was originally developed to support Bitmine's own Ethereum treasury, MAVAN has expanded to serve institutional investors, custodians, and ecosystem partners seeking best-in-class staking infrastructure. A portion of Bitmine's ETH is already staked on the MAVAN platform.

As of October 18, 2026, Bitmine total staked ETH stands at 5,067,309 ($12 billion at $2,365 per ETH). "Bitmine has staked more ETH than other entities in the world. At scale (assuming Bitmine's ETH is fully staked by MAVAN and its staking partners), the projected ETH staking reward would be $369 million on an annualized basis (using 2.58% 7-day BMNR yield). This compares to annualized staking revenues at $309 million based upon 5.1 million staked ETH (84% of the 6.04 million ETH held by Bitmine)," continued Lee.

Bitmine's crypto holdings reign as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc., which reportedly owns 848,250 BTC valued at approximately $74 billion. Bitmine remains the largest ETH treasury in the world. 

Bitmine management believes the GENIUS Act and the Securities and Exchange Commission's (SEC) Project Crypto are as transformational to financial services in 2026 as the U.S. action on August 15, 1971, which ended the Bretton Woods system and took the U.S. dollar off the gold standard 55 years ago. This 1971 event was the catalyst for the modernization of Wall Street, creating the iconic Wall Street titans and financial and payment rails of today.

The Chairman's message can be found here:
https://www.Bitminetech.io/chairmans-message

The Fiscal Full Year 2025 Earnings presentation and corporate presentation can be found here: https://Bitminetech.io/investor-relations/ 

To stay informed, please sign up at: https://Bitminetech.io/contact-us/ 

About Bitmine
Bitmine Immersion Technologies, Inc. (NYSE: BMNR), together with its subsidiaries ("Bitmine" or the "Company"), is a blockchain technology infrastructure company operating across institutional digital asset staking and validation services, bitcoin mining, and strategic digital asset management. As the world's leading Ethereum Treasury company, it implements an innovative digital asset strategy for institutional investors and public market participants. The Company provides institutional-grade staking and validation infrastructure—through which it earns staking rewards and validation income—alongside bitcoin mining activities. Bitmine holds digital assets strategically, generating yield on those holdings to support liquidity and capital formation. Since 2025, the Company has expanded its blockchain infrastructure capabilities, including developing and deploying MAVAN, its institutional staking and validation platform. The Company's activities further include investments in early-stage blockchain opportunities ("moonshot" investments) and ancillary mining, hosting, and consulting services.

For additional details, follow on X:
https://x.com/bitmnr
https://x.com/fundstrat

Cautionary Note on Forward Looking Statements 
This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include all statements that are not purely historical and can generally be identified by terms such as "expects," "projects," "intends," "plans," "believes," "anticipates," "estimates," "may," "will," "would," "could," "should," "view," "likely," "positioned," or similar expressions. This press release specifically contains forward-looking statements regarding: (i) the Company's goal of acquiring 5% of the total ETH supply (the "Alchemy of 5%" initiative); (ii) the Company's digital asset accumulation and treasury strategy, including statements regarding continued weekly ETH acquisitions and the Company's status as the largest ETH treasury in the world; (iii) the Company's staking operations, including projected annualized ETH staking rewards of approximately $369 million at scale, assuming the Company's ETH is fully staked by MAVAN and its staking partners, and currently projected annualized staking revenues of approximately $309 million; (iv) MAVAN's expansion to serve institutional investors, custodians, and ecosystem partners; (v) management's beliefs regarding crypto market conditions, including expectations of a coming crypto bull market and that the current cycle is likely the largest, that recent price declines represent attractive risk/reward opportunities, and that the Company is positioned to outperform the crypto bull market; (vi) management's beliefs regarding the impact of investor risk appetite, AI funding and AI model safety, geopolitical events, U.S. midterm elections, bond yields, and Korean and Taiwanese market conditions on crypto markets, and crypto's exposure to modernizing global financial system rails and agentic-AI; (vii) management's belief that the GENIUS Act and SEC Project Crypto are transformational to financial services; and (viii) statements regarding the value of the Company's crypto, cash, marketable securities, and "moonshot" holdings, including the indirect exposure to OpenAI provided by the Company's investment in Eightco Holdings.

These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: the extreme volatility and unpredictability of digital asset prices, including ETH and Bitcoin; the Company's reliance on third-party pricing sources and reported market values, which may fluctuate materially; changes in market conditions affecting the trading price and volume of the Company's securities; the Company's ability to successfully execute its digital asset acquisition strategy and achieve its ETH accumulation targets, including the "Alchemy of 5%" goal; the Company's ability to finance its business operations and MAVAN expansion; operational, security, and technological risks associated with the Company's staking and validation operations, including network failures, slashing events, cybersecurity breaches, and protocol changes; the risk that actual staking yields, rewards, and revenues differ materially from projected amounts, including if the Company's ETH is not fully staked; competition in the digital asset treasury, staking, and mining industries; the Company's dependence on key personnel; regulatory developments affecting digital assets, blockchain technology, and staking activities, including the ultimate enactment, implementation, and interpretation of the GENIUS Act and other pending legislation; actions by the SEC, CFTC, and other regulatory bodies; risks related to the Company's "moonshot" investments, including in Eightco Holdings and Beast Industries; macroeconomic and geopolitical factors, including inflation, interest rates, bond yields, military conflicts, elections, and general economic conditions; volatility in AI-related and semiconductor equities and in foreign markets, including Korea and Taiwan; changes to the Ethereum protocol; the performance of third-party service providers, exchanges, custodians, and staking partners; and the other risk factors described in the Company's filings with the SEC.

The forward-looking statements contained in this press release are based on information available to management as of the date of this release and reflect management's current expectations, estimates, and beliefs concerning future events. Actual results may vary materially from those expressed or implied based on the factors described above and in the Risk Factors section of the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025 filed with the SEC on November 21, 2025, the Company's Quarterly Reports on Form 10-Q, and the Company's other filings with the SEC, as amended or updated from time to time. Copies of these filings are available at www.sec.gov and at https://Bitminetech.io/investor-relations/. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Bitmine expressly disclaims any obligation to update or revise any forward-looking statements except as required by applicable law.

SOURCE Bitmine Immersion Technologies, Inc.

Secures a key centrifuge component supplier and best-in-class manufacturer with an existing and growing business

Diversifies revenue base by expanding Centrus' addressable market with significant adjacent, non-nuclear manufacturing work

Drives continued growth for both organizations through commercial and operational synergies and cost savings

, /PRNewswire/ -- Centrus Energy Corp. (NYSE: LEU) ("Centrus"), a trusted supplier of nuclear fuel and services, today announced that it has acquired Westerman Holdings, LLC ("Westerman"), one of Centrus' largest and most diversified suppliers, for approximately $116 million, funded through a combination of approximately $95 million cash on hand and $21 million of equity. The transaction is expected to be accretive to adjusted earnings per share in the first year following closing.

The acquisition represents a significant milestone for Centrus as it builds supply chain resilience while diversifying its revenue base. Westerman's expertise strengthens and de-risks Centrus' supply chain by securing and bringing in-house its critical manufacturing capabilities. The acquisition simultaneously broadens Centrus' manufacturing platform, customer base, and future revenue opportunities through commercial and operational synergies.

The addition of Westerman supports Centrus' previously announced multi-billion-dollar expansion of uranium enrichment capacity. Westerman is an existing manufacturer for centrifuge casings and other major centrifuge components for Centrus. With the acquisition, Centrus intends to secure this key supplier while expanding Westerman's capabilities. Westerman currently services a number of non-nuclear customers across a variety of industries including oil and gas as well as other high-growth industrial sectors, diversifying Centrus' revenue base beyond its core nuclear business. The acquisition is expected to result in lower project costs for Centrus and greater efficiencies with an integrated supply chain.

"Westerman is a highly regarded, best-in-class supplier and fabricator for Centrus, the broader nuclear industry, and a number of other sectors," said Amir Vexler, President and CEO of Centrus. "Bringing Westerman in-house demonstrates our commitment to securing our supply chain to support our build-out while adding to our capabilities and expanding our customer base.  We are committed to growing and expanding Westerman alongside our enrichment business, and are confident that this transaction will unlock significant value for our shareholders." 

"Westerman has spent more than a century building advanced, differentiated manufacturing capabilities," said Jacob Garrett, CEO of Westerman, who will now transition to President of Westerman and also become a Vice President of Centrus Energy. "Joining with Centrus will allow us to accelerate that trajectory. Together, we can expand our production, deepen our nuclear manufacturing portfolio, and create new opportunities for our employees, our customers, and our communities. We are excited for the future we will build together."

Centrus acquired all of Westerman's business lines and Westerman has become a subsidiary within Centrus. Westerman will continue to operate under the Westerman name, leveraging its brand identity and customer relationships.

Founded in 1909, Westerman is an established, high-quality industrial fabrication manufacturer with specialized capabilities serving the nuclear, oil and gas, and broader high-growth industrial markets. With approximately 400 employees and four world-class facilities in Ohio, Oklahoma, and Wyoming, Westerman provides a broad portfolio of products that span upstream and midstream oil and gas production equipment, engineered industrial systems, and nuclear‑grade products including UF6 cylinders.

Barclays served as financial advisor to Centrus and Wachtell, Lipton, Rosen & Katz served as legal counsel to Centrus for this transaction.

About Centrus

Centrus Energy is a trusted American supplier of nuclear fuel and services for the nuclear power industry, helping meet the growing need for clean, affordable, carbon-free energy. Since 1998, the Company has provided its utility customers with more than 1,850 reactor years of fuel, which is equivalent to more than 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is pioneering production of High-Assay, Low-Enriched Uranium and is leading the effort to restore America's uranium enrichment capabilities at scale so that we can meet our clean energy, energy security, and national security needs. Find out more at www.centrusenergy.com or follow us on LinkedIn and X.

About Westerman

Westerman is a large equipment fabricator, focused on continuous improvements in design, engineering, and manufacturing. Our broad portfolio of equipment supports production, dehydration, stabilization, filtration, and custody transfer metering, setting new standards for performance and economics nationwide. We proudly serve other diverse end markets such as Nuclear, Marine, and Industrial. 

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "will", "should", "could", "would" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions with respect to future events and operational, economic and financial performance.

For Centrus Energy Corp., particular factors that involve uncertainty and could cause our actual future results to differ materially from those expressed in our forward-looking statements and which are, and may be, exacerbated by any worsening of the global business and economic environment include but are not limited to the following: the war in Ukraine and other geopolitical conflicts; our government contracts, including related to changes to the U.S. government's appropriated funding levels for HALEU and the government's inability to satisfy its obligations, and our lease to our facility in Piketon, Ohio; whether or when government demand for HALEU or LEU for government or commercial uses will materialize and at what level; the impact and potential extended duration of a supply/demand imbalance in the market for LEU; significant competition from major LEU producers, including foreign competitors, who may be less cost sensitive than we are; limitations on our ability to compete in foreign markets; pricing trends and demand in the uranium and enrichment markets, especially in light of the potential of limited supply and our dependence on others for deliveries of LEU; and our ability to successfully implement our planned expansion projects in Piketon, Ohio and Oak Ridge, Tennessee.

Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this news release and in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, under Part II, Item 1A – "Risk Factors" in our Quarterly report on Form 10-Q for the quarter ended March 31, 2026, under Part II, Item 1A – "Risk Factors" in our Quarterly report on Form 10-Q for the quarter ended June 30, 2026, and our filings with the SEC that attempt to advise interested parties of the risks and factors that may affect our business. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Contacts: 

Centrus (Media) — Dan Leistikow [email protected]
Centrus (Investors) — Neal Nagarajan [email protected]
Westerman — Nolan Lamar [email protected]

SOURCE Centrus Energy Corp.